Evidence map›Paper›PMID 38820140›Full record

ArticleScience immunology2024

The tumor-intrinsic role of the m

Sai Xiao, Shoubao Ma, Baofa Sun, Wenchen Pu, Songqi Duan, Jingjing Han, Yaqun Hong, Jianying Zhang, Yong Peng, Chuan He and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed.

  1. Article
  2. Loss of NCCRP1 overcomes immune evasion in lung adenocarcinoma.Journal for immunotherapy of cancer · 2026
    Article
  3. Review
  4. The relevance of mJournal of cancer research and clinical oncology · 2026
    Review
  5. Article
  6. RNA modifications in cancer and their detection: a review.Japanese journal of clinical oncology · 2026
    Review
  7. Review
  8. Review
  9. miR-493-3p alleviates carotid artery stenosis by targeting YTHDF2.Journal of thrombosis and thrombolysis · 2026
    Article
  10. Emerging roles of RNA mInternational journal of oncology · 2026
    Review
  11. Targeting intracellular mRNA mJournal of advanced research · 2026
    Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Sai XiaoDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, CA 91010, USA.
Shoubao MaDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, CA 91010, USA.
Baofa SunState Key Laboratory of Medicinal Chemical Biology, Frontiers Science Center for Cell Responses, College of Life Sciences, Nankai University, Tianjin 300071, China.
Wenchen PuLaboratory of Molecular Oncology, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Chengdu, China.
Songqi DuanCollege of Food Science, Sichuan Agricultural University, Ya'an, Sichuan 625014, China.
Jingjing HanDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, CA 91010, USA.
Yaqun HongDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, CA 91010, USA.
Jianying ZhangDepartment of Computational and Quantitative Medicine, City of Hope National Medical Center, Los Angeles, CA 91010, USA.
Yong PengLaboratory of Molecular Oncology, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Chengdu, China.
Chuan HeDepartment of Chemistry, Department of Biochemistry and Molecular Biology, and Institute for Biophysical Dynamics, University of Chicago, Chicago, IL 60637, USA.
Ping YiThird Affiliated Hospital of Chongqing Medical University, Chongqing 401120, China.
Michael A CaligiuriDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, CA 91010, USA.
Jianhua YuDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, CA 91010, USA.

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI XIWEI WU · 1985 to 2026
$86.3M
The Tumor Microenvironmental Barrier to Effective Viral OncolysisP01CA163205 · NCI · OHIO STATE UNIVERSITY · PI Balveen Kaur · 2013 to 2026
$26.0M
Human natural killer cells: Advancing biology and clinical applicationsR35CA210087 · NCI · OHIO STATE UNIVERSITY · PI MICHAEL A CALIGIURI · 2017 to 2026
$8.3M
cGMP Manufacture, Fill-Finish, Release, Analytical and Stability Testing and Stability Program of a Nanoparticle Based HIV Envelope Vaccine75N93022D00005 · NIAID · INTERNATIONAL AIDS VACCINE INITIATIVE · PI HASSELL, THOMAS · 2022 to 2025
$8.0M
Tasquinimod as an adjunct to immunotherapies administered peri-operativelyU19CA264512 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI Behnam Badie, Jana Portnow · 2021 to 2026
$6.0M
Task Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00005 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WATSON, KAROL E · 2020 to 2025
$5.1M
Targeting FLT3 for the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaR01CA265095 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI BUDDE, LIHUA ELIZABETH, CALIGIURI, MICHAEL A · 2021 to 2025
$2.4M
Characterizing and Targeting the Novel IL-15- AKT-XBP1s Pathway in NK CellsR01CA247550 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI YU, JIANHUA · 2020 to 2024
$2.2M
Elucidate and Modulate Cell Signaling in NK Cells for Glioma TreatmentR01AI129582 · NIAID · OHIO STATE UNIVERSITY · PI YU, JIANHUA · 2017 to 2021
$2.1M
Overcoming Barriers of Virotherapy by Next-Generation oHSV Expressing E-CadherinR01NS106170 · NINDS · OHIO STATE UNIVERSITY · PI YU, JIANHUA · 2018 to 2023
$1.9M
Phase 1 Evaluation of Enhanced Natural Killer Cells as a Treatment Strategy in Non-Small cell Lung Cancer Patients Refractory to PD-1/PD-L1 Immune Checkpoint InhibitorsR01CA266457 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI VILLALONA, MIGUEL A, YU, JIANHUA · 2022 to 2025
$1.8M
NCI NIH HHS P01 CA163205NCI NIH HHS P30 CA033572NCI NIH HHS R01 CA247550NCI NIH HHS R01 CA265095NCI NIH HHS R01 CA266457NCI NIH HHS R35 CA210087NCI NIH HHS U19 CA264512NHLBI NIH HHS 75N92020D00005NIAID NIH HHS 75N93022D00005NIAID NIH HHS 75N93023D00005NIAID NIH HHS R01 AI129582NIDA NIH HHS 75N95020D00005NINDS NIH HHS R01 NS106170ORFDO NIH HHS 75N99020D00005
6 · The paper itself

Abstract

Tumors evade attacks from the immune system through various mechanisms. Here, we identify a component of tumor immune evasion mediated by YTH domain-containing family protein 2 (YTHDF2), a reader protein that usually destabilizes m

Indexed as

Immune EvasionRNA-Binding ProteinsAdenosineAnimalsCD8-Positive T-LymphocytesCell Line, TumorFemaleHumansMiceMice, Inbred C57BLMice, KnockoutNeoplasmsRNA MethylationTumor EscapeAdenosineN-methyladenosineRNA-Binding ProteinsYTHDF2 protein, humanYTHDF2 protein, mouse

Identifiers

PMID38820140
PMCPMC12068375

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.